Topcare Medical Group INC
Topcare Medical Group INC was paid $42.63M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 29% of everything it billed.
33Billing provider infoTOPCARE MEDICAL GROUP INC
DALLAS, TX 75251
DALLAS, TX 75251
33aNPI1730337163assigned 08/27/2008
33bProvider typeSpecialist
28Total paid$42.63M
24GClaims2,448,246
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in Texas
Rank by total paid#1 of 382
Median peer was paid$29K
This provider vs. median1,473×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,268 | $431K | |
| 2019 | 15,187 | $399K | |
| 2020 | 181,645 | $2.63M | |
| 2021 | 565,270 | $11.16M | |
| 2022 | 630,350 | $10.26M | |
| 2023 | 566,569 | $9.88M | |
| 2024incomplete | 471,957 | $7.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 29% | 372,791 | 336,396 | $12.30M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 15% | 213,570 | 202,164 | $6.28M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 226,605 | 207,343 | $5.43M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 8.1% | 57,545 | 56,638 | $3.45M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.4% | 55,499 | 54,887 | $3.14M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 5.0% | 293,743 | 151,154 | $2.13M |
| 87400 | 3.6% | 205,391 | 99,012 | $1.52M | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.5% | 28,318 | 27,832 | $1.49M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.0% | 108,411 | 64,107 | $1.26M |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.5% | 113,968 | 108,491 | $1.05M |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.8% | 14,299 | 13,918 | $756K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.2% | 8,588 | 8,046 | $517K |
146 more codes
| 99429 | <1% | 16,997 | $392K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 8,641 | $281K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,498 | $242K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,398 | $216K |
| 99000 | <1% | 25,725 | $168K | |
| 99381 | <1% | 2,099 | $163K | |
| 99384 | <1% | 1,977 | $161K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 28,887 | $160K |
| 80053 | Comprehensive metabolic panel | <1% | 25,515 | $157K |
| 90461 | <1% | 49,986 | $140K | |
| 80061 | Lipid panel | <1% | 19,900 | $132K |
| 99383 | <1% | 1,515 | $125K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,789 | $119K |
| 87807 | <1% | 13,515 | $94K | |
| 96160 | <1% | 73,339 | $88K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,414 | $83K |
| 99091 | <1% | 722 | $81K | |
| 99382 | <1% | 771 | $65K | |
| 99385 | <1% | 1,154 | $64K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,848 | $44K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,894 | $34K |
| 90686 | <1% | 62,107 | $34K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,507 | $31K |
| 81003 | <1% | 18,920 | $25K | |
| 0071A | <1% | 787 | $25K | |
| 0072A | <1% | 485 | $16K | |
| 0001A | <1% | 439 | $15K | |
| 83013 | <1% | 342 | $12K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 481 | $11K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 187 | $11K |
| 0002A | <1% | 282 | $10K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,763 | $9K |
| 85027 | <1% | 2,655 | $9K | |
| 97169 | <1% | 1,004 | $8K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,651 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 542 | $7K |
| 82044 | <1% | 1,657 | $6K | |
| 82570 | <1% | 1,659 | $5K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 474 | $5K |
| 83655 | <1% | 955 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 177 | $5K |
| 90651 | <1% | 25,126 | $4K | |
| 81025 | <1% | 913 | $4K | |
| 94375 | <1% | 202 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 440 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 192 | $3K |
| 92567 | <1% | 324 | $3K | |
| 87428 | <1% | 200 | $3K | |
| 90656 | <1% | 7,235 | $2K | |
| 90620 | <1% | 3,830 | $2K | |
| 90734 | <1% | 9,331 | $2K | |
| 99050 | <1% | 290 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 595 | $1K |
| 83014 | <1% | 317 | $1K | |
| 94760 | <1% | 2,275 | $981.87 | |
| 93000 | <1% | 92 | $852.91 | |
| 85018 | <1% | 682 | $843.41 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 175 | $842.39 |
| 0011A | <1% | 160 | $751.98 | |
| 3074F | <1% | 26,906 | $650.03 | |
| 92551 | <1% | 5,613 | $629.91 | |
| 92552 | <1% | 114 | $553.98 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,064 | $449.56 |
| 94060 | <1% | 32 | $443.84 | |
| 99490 | Ccm add 20min | <1% | 62 | $423.70 |
| 69210 | <1% | 13 | $367.81 | |
| 90480 | <1% | 13 | $366.00 | |
| 0052A | <1% | 12 | $360.00 | |
| 0012A | <1% | 133 | $262.89 | |
| 99406 | <1% | 29 | $208.48 | |
| 90619 | <1% | 2,510 | $178.09 | |
| 99349 | <1% | 33 | $175.78 | |
| 96380 | <1% | 16 | $165.12 | |
| 90715 | <1% | 2,712 | $162.92 | |
| 90670 | <1% | 6,520 | $120.00 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 194 | $109.01 |
| 99343 | <1% | 34 | $108.35 | |
| 0013A | <1% | 13 | $80.00 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 536 | $66.43 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 541 | $60.53 |
| 98960 | <1% | 90 | $50.30 | |
| 90660 | <1% | 227 | $38.50 | |
| 3075F | <1% | 1,713 | $25.01 | |
| 3077F | <1% | 1,301 | $25.00 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 110,239 | $24.74 |
| 99080 | <1% | 152 | $19.09 | |
| 69209 | <1% | 14 | $11.36 | |
| 90677 | <1% | 1,953 | $7.35 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 225 | $5.58 |
| 90697 | <1% | 1,281 | $0.63 | |
| 92558 | <1% | 33 | $0.09 | |
| 90621 | <1% | 627 | $0.05 | |
| 3078F | <1% | 21,272 | $0.04 | |
| 3008F | <1% | 43,810 | $0.01 | |
| 90716 | <1% | 1,713 | $0.01 | |
| 91307 | 0% | 1,817 | $0.00 | |
| 90696 | 0% | 980 | $0.00 | |
| 90723 | 0% | 2,457 | $0.00 | |
| 3079F | 0% | 8,747 | $0.00 | |
| 1111F | 0% | 267 | $0.00 | |
| 90680 | 0% | 1,096 | $0.00 | |
| 1030F | 0% | 4,670 | $0.00 | |
| 36416 | 0% | 1,758 | $0.00 | |
| 3080F | 0% | 549 | $0.00 | |
| 90744 | 0% | 67 | $0.00 | |
| 1170F | 0% | 202 | $0.00 | |
| 1126F | 0% | 32 | $0.00 | |
| 4037F | 0% | 1,159 | $0.00 | |
| 3044F | 0% | 129 | $0.00 | |
| 90698 | 0% | 174 | $0.00 | |
| 91305 | 0% | 135 | $0.00 | |
| 91301 | 0% | 89 | $0.00 | |
| 90381 | 0% | 13 | $0.00 | |
| 90688 | 0% | 97 | $0.00 | |
| 97802 | 0% | 732 | $0.00 | |
| 96127 | 0% | 248 | $0.00 | |
| 1036F | 0% | 21 | $0.00 | |
| 99441 | 0% | 115 | $0.00 | |
| A9150 | Non-prescription drugs | 0% | 12 | $0.00 |
| 4010F | 0% | 20 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 50 | $0.00 |
| 99489 | Ccm add 20min | 0% | 16 | $0.00 |
| 90633 | 0% | 4,757 | $0.00 | |
| 99173 | 0% | 9,424 | $0.00 | |
| 4274F | 0% | 1,212 | $0.00 | |
| 90707 | 0% | 1,718 | $0.00 | |
| 90648 | 0% | 4,526 | $0.00 | |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | 0% | 1,754 | $0.00 |
| 90710 | 0% | 1,603 | $0.00 | |
| 91300 | 0% | 1,006 | $0.00 | |
| 90681 | 0% | 651 | $0.00 | |
| 90700 | 0% | 434 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 285 | $0.00 |
| 1159F | 0% | 210 | $0.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 399 | $0.00 |
| 1160F | 0% | 210 | $0.00 | |
| G9498 | Antibiotic regimen prescribed | 0% | 69 | $0.00 |
| 90649 | 0% | 303 | $0.00 | |
| 90756 | 0% | 34 | $0.00 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 12 | $0.00 |
| 3015F | 0% | 45 | $0.00 | |
| 4551F | 0% | 129 | $0.00 | |
| 3725F | 0% | 76 | $0.00 | |
| G8482 | Influenza immunization administered or previously received | 0% | 169 | $0.00 |
| 99051 | 0% | 40 | $0.00 | |
| 2021F | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSAENZ, ALVARO (CEO)
| Provider | Location | Paid |
|---|---|---|
| Topcare Medical Group INC | Dallas, TX | $160.36M |
| Topcare Medical PA | Irving, TX | $561.39 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.